CLOV three-lens brief
Evidence-based stock research on CLOV. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -3.31% yesterday.
- Moved -3.31% yesterday.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 25.7pp over 30 days.
- Earnings scheduled 2026-08-04.
CLOV closed at $4.53 (-3.31%) as of 2026-07-10. Market cap: $2.38B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 25.7pp over 30 days.. Concerns: moved -3.31% yesterday.. Last quarter: Revenue $749.19M, net income $27.33M, free cash flow $75.08M. Watching for: 2026-08-04 earnings release (24 days out).
Why three lenses on CLOV, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CLOVacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CLOV" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CLOV brief"></iframe>